Skip to main content
SpringerLink
Log in

IL17 inhibitors do not increase risk of IBD versus etanercept

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Penso L, et al. Risk of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis initiating interleukin 17 inhibitors: a nationwide population-based study using the French national health data system. Arthritis and Rheumatology : 19 Jul 2021. Available from: URL: http://doi.org/10.1002/art.41923

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

IL17 inhibitors do not increase risk of IBD versus etanercept. Reactions Weekly 1866, 8 (2021). https://doi.org/10.1007/s40278-021-99704-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-99704-x

Search

Navigation